Skip Navigation LinksHome > March 2014 - Volume 42 - Issue 3 > Evaluating the Efficacy and Safety of Two Doses of the Polyc...
Critical Care Medicine:
doi: 10.1097/CCM.0000000000000043
Feature Articles

Evaluating the Efficacy and Safety of Two Doses of the Polyclonal Anti-Tumor Necrosis Factor-α Fragment Antibody AZD9773 in Adult Patients With Severe Sepsis and/or Septic Shock: Randomized, Double-Blind, Placebo-Controlled Phase IIb Study*

Bernard, Gordon R. MD1; Francois, Bruno MD2; Mira, Jean-Paul MD3; Vincent, Jean-Louis MD, PhD, FCCM4; Dellinger, R. Phillip MD5; Russell, James A. MD6; LaRosa, Steven P. MD7; Laterre, Pierre-Francois MD8; Levy, Mitchell M. MD9; Dankner, Wayne MD10; Schmitt, Nicola MPhil11; Lindemann, Justin MBChB11; Wittebole, Xavier MD8

Supplemental Author Material
Collapse Box


Objective: This trial compared the efficacy/safety of two IV doses of AZD9773, a polyclonal antibody to tumor necrosis factor-α, in adult patients with severe sepsis/septic shock.

Design: Multicenter, randomized, double-blind, placebo-controlled phase IIb trial.

Setting: ICUs in seven countries (Australia, Belgium, Canada, Czech Republic, Finland, France, and Spain).

Patients: Patients 18 years old or older with severe sepsis and/or septic shock. Patients were required to have 1) objective clinical evidence of infection; 2) at least two of four systemic inflammatory response syndrome criteria; and 3) cardiovascular and/or respiratory sepsis-related failure.

Interventions: Patients were randomized 1:1:1 to a single loading infusion of AZD9773 250 U/kg followed by 50 U/kg every 12 hours (low dose, n = 100), a single loading infusion of AZD9773 500 U/kg followed by 100 U/kg every 12 hours (high dose, n = 100), or placebo (n = 100) for 5 days. Follow-up assessments were performed up to day 90.

Measurements and Main Results: Mean number of ventilator-free days (primary endpoint) did not differ between low-dose (19.7 d) or high-dose AZD9773 (17.3 d) and placebo (18.3 d) (one-sided p = 0.18 and 0.74, respectively). Mortality rates were comparable across treatment groups; relative risk of death versus placebo at day 29 was 0.80 for low-dose AZD9773 (one-sided p = 0.25) and 1.64 for high-dose AZD9773 (p = 0.97). Most patients experienced at least one treatment-emergent adverse event (87.8% in AZD9773-treated patients, 92.9% in placebo patients) although most were mild/moderate in nature. No differences in the incidence of adverse events or laboratory or vital sign abnormalities were observed between groups.

Conclusions: AZD9773 rapidly and efficiently decreased plasma tumor necrosis factor-α concentration in patients with severe sepsis/septic shock, but this effect did not translate into clinical benefit.

© 2014 by the Society of Critical Care Medicine and Lippincott Williams & Wilkins

Article Tools


Article Level Metrics

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.